Respira Therapeutics, a product development company focused on inhaled therapeutics to improve patients' lives, today announced the results of a clinical feasibility study of the Company's drug engine technology.

Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration for ciprofloxacin dry powder inhaler for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis patients. A similar designation has already been granted by the European Medicines Agency.